The combination of a negative D-dimer and a Wells score can rule out, but not confirm, a diagnosis of deep venous thrombosis (DVT). We aimed to identify new diagnostic biomarkers for DVT and to investigate their relationship with hypercoagulability markers [D-dimer and activated protein C-protein C inhibitor (APC-PCI) complex]. We screened 92 cardiovascular-specific proteins in plasma samples from 45 confirmed DVT patients and 45 age-and sex-matched non-DVT patients selected from a prospective multicentre diagnostic management study (SCORE) by Proseek Multiplex CVDIII 96996 . Plasma levels of 30 proteins were significantly different between DVT and non-DVT patients. After Bonferroni correction, plasma levels of seven proteins: P-selectin, transferrin receptor protein 1, von Willebrand factor, tissue factor pathway inhibitor, osteopontin (OPN), bleomycin hydrolase and ST2 protein remained significantly different. The area under curve (AUC) for these proteins ranged from 0Á70 to 0Á84. Furthermore, all seven identified proteins were significantly associated with markers of hypercoagulability. A combination of OPN and APC-PCI had the best ability to discriminate DVT from non-DVT patients (AUC = 0Á94; sensitivity = 89% and specificity = s84%). In conclusion, we identified multiple proteins associated with markers of hypercoagulability and with a potential to become novel diagnostic biomarkers for DVT.
Summary
The combination of a negative D-dimer and a Wells score can rule out, but not confirm, a diagnosis of deep venous thrombosis (DVT). We aimed to identify new diagnostic biomarkers for DVT and to investigate their relationship with hypercoagulability markers [D-dimer and activated protein C-protein C inhibitor (APC-PCI) complex]. We screened 92 cardiovascular-specific proteins in plasma samples from 45 confirmed DVT patients and 45 age-and sex-matched non-DVT patients selected from a prospective multicentre diagnostic management study (SCORE) by Proseek Multiplex CVDIII 96996 . Plasma levels of 30 proteins were significantly different between DVT and non-DVT patients. After Bonferroni correction, plasma levels of seven proteins: P-selectin, transferrin receptor protein 1, von Willebrand factor, tissue factor pathway inhibitor, osteopontin (OPN), bleomycin hydrolase and ST2 protein remained significantly different. The area under curve (AUC) for these proteins ranged from 0Á70 to 0Á84. Furthermore, all seven identified proteins were significantly associated with markers of hypercoagulability. A combination of OPN and APC-PCI had the best ability to discriminate DVT from non-DVT patients (AUC = 0Á94; sensitivity = 89% and specificity = s84%). In conclusion, we identified multiple proteins associated with markers of hypercoagulability and with a potential to become novel diagnostic biomarkers for DVT.
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Deep vein thrombosis (DVT) is a blood clot that forms in deep veins, and mostly occurs in the lower extremities. DVT is the third most common cardiovascular disease (CVD) with an estimated annual incidence of 1-2 in 1000 individuals in the general population (Silverstein et al, 1998; Rosendaal, 1999; White, 2003; Naess et al, 2007; Severinsen et al, 2010; Goldhaber & Bounameaux, 2012) . The most severe complication is pulmonary embolism (PE) which is associated with significant numbers of deaths annually (Anderson et al, 1991) . Patients with suspected DVT are common in hospital emergency departments, with diffuse symptoms such as tenderness or swelling in the leg; however, relatively few suspected patients actually have DVT (Hull & Hirsh, 1981; Wells et al, 2006) . In recent years, clinical probability scores (based on patient symptoms, signs and medical history) have been used to determine whether a further diagnostic test or examination is required. Furthermore, use of D-dimer analysis has proven successful in combination with the Wells score in excluding 30-50% of outpatients with suspected DVT and thereby safely precluding the need of further testing in these patients (Wells et al, 2006) . However, D-dimer assays are not standardized, have low specificity and the performance varies substantially between assays and populations (Stein et al, 2004; Di Nisio et al, 2007) . A positive Ddimer test always needs to be confirmed with an objective method, such as ultrasound, in order to determine the DVT diagnosis. Ultrasound may, however, not always be available and can be expensive and inefficient, especially when a majority of suspected DVT patients are finally diagnosed as DVT negative. Currently, there are no further biomarker tests available that can confirm the DVT diagnosis in the absence of radiological examination. Therefore, identification of novel biomarkers is not only crucial for better diagnosis and management but may also help in better understanding the molecular pathways involving DVT pathogenesis. Recent advances in biomarker research have enabled high throughput detection of protein biomarkers. For example, a new technology, the proximity extension assay, has enabled simultaneous screening of 92 proteins with high sensitivity and specificity in small biological sample volumes (Lundberg et al, 2011; Assarsson et al, 2014) . In this exploratory study, we used this robust immunoassay to investigate the potential role of 92 circulating proteins with proposed involvement in inflammation and CVD with the aim to identify new diagnostic biomarkers for DVT. In addition, we also aimed to examine the associations between newly identified DVT biomarkers with the markers of hypercoagulability, i.e. Ddimer and the activated protein C-protein C inhibitor (APC-PCI) complex.
Material and methods

Study subjects and sample collection
The study subjects were selected from a prospective multicentre management study, in which 357 consecutive patients with a suspected first episode of DVT were included (Elf et al, 2009 (Elf et al, , 2010 . Briefly, patients were recruited from seven hospitals in southern Sweden between December 2003 and December 2005. The inclusion criteria were adults with a suspected first episode of DVT by either self-referral, or referral from primary care physicians or other clinics. Diagnosis of DVT patients was made by a combination of the Wells score (Wells et al, 1997) and D-dimer test as well as contrast venography and/or compression ultrasound (CUS). All the patients were evaluated by the Wells score (Wells et al, 1997) and were categorized with low, intermediate or high pre-test probability. Patients with low pre-test probability were then analysed for D-dimer levels and, if the D-dimer test was negative, DVT was ruled out. These patients were observed for 3 months. None of the included patients had DVT during the three-month follow-up. Patients with low, intermediate or high pre-test probability and positive Ddimer test were investigated with contrast venography or CUS. If the CUS result was negative, comprehensive ultrasound (including calf veins) or contrast venography was performed. Thus, all DVT positive were objectively confirmed. Exclusion criteria for this study included: previous venous thrombosis, duration of symptoms >10 days, inability or unwillingness to provide information, pregnancy, suspected pulmonary embolism, ongoing anticoagulation and inadequate or missing case report forms. A total of 350 patients met the inclusion criteria and plasma was available from 238 patients (age 16-95 years). In total, 53 patients were diagnosed with DVT and 185 had no DVT diagnosed with objective methods as described above. For this exploratory study we selected 90 samples that could be analysed in Multiplex CVD III 96*96 panel (Olink Biosciences, Uppsala, Sweden); plasma samples from 45 objectively diagnosed DVT patients and 45 age-and sex-matched non-DVT patients were used for the evaluation of 92 CVD-related proteins. The clinical characteristics of the study population are presented in Table I . The study was performed according to the principles of the Declaration of Helsinki. All the patients gave their informed written consent before enrolment. The present analysis was reviewed and approved by the Ethics Committee of Lund University, prior to its commencement, on 5 October 2015 (application no. 2015/491).
Sample preparation
Fasting venous blood (5 ml) was collected in vacuum tubes (Becton-Dickinson, Franklin Lakes, NJ, USA) containing sodium-citrate (3Á8%). Blood samples were centrifuged at 3600 g for 10 min at 4°C within 30 min of collection, and the plasma was then aliquoted and stored at À70°C for later analyses in batch for the Vidas â D-dimer, APC-PCI and protein biomarkers. Table I . Clinical data of the patients included for screening potential diagnostic biomarkers for DVT. (Lundberg et al, 2011) . Briefly, 92 oligonucleotide-labelled antibody probe pairs that, upon simultaneous binding to the target analyte, create a real-time polymerase chain reaction (PCR) amplicon by a proximitydependent DNA polymerization event and the resulting sequence is subsequently detected and quantified using standard real-time PCR. The raw data were normalized and are presented as normalized protein expression (NPX). NPX values were obtained by normalizing cq-values against extension control, interplate control and a correction factor. NPX values are on log2 scale where a high NPX value corresponds to a high protein concentration and can be linearized by using the formula 2^NPX. The limit of detection (LOD) is determined for each biomarker based on the negative controls analysed in each run.
Protein biomarkers screening
Variables DVT (n = 45) Non-DVT (n = 45) P-value Age, years Mean (SD) 62Á0 (19Á2) 62Á0 (17Á2) 0Á9 Sex Male/female (%) 50/50 50/50 1Á00 Log APC-PCI a Mean (SD) À0Á34 (1Á2) À1Á7 (0Á3) <0Á0001 BMI b Mean (SD) 26Á0 (4Á9) 26Á8 (3Á8) 0Á3
D-dimer and APC-PCI complex
D-dimer analysis was performed by Vidas
â D-dimer Exclusion assay (Biom erieux, MarcyEtoile, France) (Elf et al, 2009) . Briefly, 5 ml venous blood was collected in vacuum tubes containing sodium-citrate (3Á8%) (Becton-Dickinson,). These tubes were centrifuged at 3600 9 g at 4°C for 10 min to obtain platelet-poor plasma. An immunochemical sandwich method was used to determine APC-PCI complex concentration as described previously (Strandberg et al, 2001 ).
Statistical analysis
Patient characteristics are presented as mean and standard deviation (SD) for the continuous variables and number and percentages for the categorical variables. APC-PCI, D-dimer were transformed with the natural logarithm due to skewed distributions. Plasma levels of biomarkers were compared between DVT and non-DVT samples by t-test. Bonferroni and Hochberg methods were employed for multiple testing. Pearson's correlations were used to examine the correlations between the protein biomarkers and APC-PCI and D-dimer. Receiver-operating characteristic (ROC) curves were used to analyse the diagnostic potential of the protein biomarkers. This curve plot represents the true positive rate (also known as sensitivity) against the false positive rate (1-specificity) and the accuracy is measured by the area under the curve (AUC). An AUC value of 1 represents a perfect test while an AUC of 0Á5 indicates no predictive power of the test. To obtain the optimal cut-off point to discriminate the DVT patients from non-DVT patients, we used the Youden Index method (Youden, 1950) . AUC values and 95% confidence intervals together with sensitivity and specificity as well as ROC curves for protein biomarkers are presented. SAS V 9Á3 (SAS Institute, Cary, NC, USA) was used for all statistical analyses. Table I shows the clinical data in the SCORE study population (Elf et al, 2009 (Elf et al, , 2010 included in this study for screening of potential diagnostic biomarkers for DVT (Table SII shows the clinical data on the whole population). In total, 45 patients each diagnosed with DVT or non-DVT were matched for age and sex. There was no significant difference in body mass index, smoking status and family history between DVT and non-DVT patients. APC-PCI levels were significantly higher in DVT patients compared to non-DVT patients. Similarly, levels of D-dimer were significantly higher in DVT patients compared to non-DVT patients (Table I) . Levels of APC-PCI were comparable between selected population in this study and the whole population (Table I vs.  Table SI) .
Results
Identification of new diagnostic markers of DVT
In total, 92 proteins were screened (Table SIII shows comparisons of all protein biomarkers analysed in this study). In total, plasma levels of 30 proteins were significantly different between DVT and non-DVT patients. However, after Bonferroni and Hochberg corrections, the levels of seven proteins; P-selectin (SELP), transferrin receptor protein 1 (TR), von Willebrand factor (VWF), tissue factor pathway inhibitor (TFPI), osteopontin (OPN), bleomycin hydrolase (BLM hydrolase) and ST2 protein (ST2) remained significantly higher in patients with DVT compared to non-DVT patients (Table II) .
Association between protein biomarkers and markers of hypercoagulability
We used the Pearson correlation coefficient to examine the strength and direction of the linear relationship between the biomarkers. We found a strong correlation between D-dimer and SELP, TR, VWF, TFPI, OPN, BLM hydrolase and ST2. Furthermore, all protein biomarkers except OPN, were significantly correlated with APC-PCI (Table III) .
Protein biomarkers and risk of DVT
Logistic regression analysis for standardized biomarkers (mean = 0 and SD = 1) showed that higher levels of SELP [odds ratio; 95% confidence interval (CI), 5Á71; 2Á75-11Á88], TR (3Á57; 1Á95-6Á54), VWF (3Á53; 1Á89-6Á60), TFPI (2Á58; 1Á50-4Á42), OPN (2Á55; 1Á48-4Á39), BLM hydrolase (2Á41; A. A. Memon et al 1Á43-4Á06) and ST2 (2Á66; 1Á46-4Á85)were significantly associated with higher risk of DVT (Table IV) .
Diagnostic potential of identified protein biomarkers
To evaluate the diagnostic value of the identified protein biomarkers, we performed ROC curve analysis. The AUC values and 95% CI of the protein biomarkers that remained significant after Bonferroni and Hochberg and APC-PCI were calculated, along with sensitivity and specificity. The optimal cut-off point or decision threshold was defined as the point that gave maximum correct classification. To obtain the optimal cut-off point to discriminate DVT from non-DVT, we used the Youden Index method (Youden, 1950) . Biomarkers with high discrimination ability for confirming DVT will also need a higher specificity than D-dimer tests in order to 
APC-PCI, activated protein C-protein C inhibitor complex; BLM hydrolase, Bleomycin hydrolase; OPN, Osteopontin; SELP, P-selectin; ST2, ST2 protein; TFPI, Tissue factor pathway inhibitor; TR, Transferrin receptor protein 1; VWF, von Willebrand factor. Pearson correlation coefficient and p-values for each biomarker are shown. SELP  1Á74  5Á71  2Á75-11Á88  0Á00001  TR  1Á27  3Á57  1Á95-6Á54  0Á00001  VWF  1Á26  3Á53  1Á89-6Á60  0Á00001  TFPI  0Á95  2Á58  1Á50-4Á42  0Á0006  OPN  0Á94  2Á55  1Á48-4Á39  0Á0007  BLM hydrolase  0Á88  2Á41  1Á43-4Á06  0Á001  ST2  0Á98  2Á66  1Á46-4Á85  0Á0014 95% CI, 95% confidence interval; BLM hydrolase, Bleomycin hydrolase; DVT, deep venous thrombosis; OPN, Osteopontin; OR, odds ratio; SELP, P-selectin; ST2, ST2 protein; TFPI, Tissue factor pathway inhibitor; TR, Transferrin receptor protein 1; VWF, von Willebrand factor.
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reduce the number of false positive tests. Optimal cut-off levels of each biomarker which gave the best specificity and sensitivity are shown in Table V . In order to further improve classification and the discrimination ability of these biomarkers, we tested various combinations of biomarkers by canonical correlation analysis (Johnson & Wichern, 2014) which focuses on the correlation between a linear combination of the variables. This technique seeks the weighted linear composite for each variate to maximize their correlation by ROC curve. Our results show that the combination of APC-PCI and OPN had the best diagnostic potential (AUC; 0Á94, 95% CI; 0Á89-0Á98) with a sensitivity and specificity of 89% and 84% respectively. No other combination of biomarkers showed better diagnostic value than the combination of APC-PCI and OPN. AUC, specificity and sensitivity values of all combinations are presented in Table VI .
Discussion
In this study, we evaluated the diagnostic potential of 92 CVD-related proteins in plasma samples from objectively diagnosed 45 DVT cases and 45 age-and sex-matched non-DVT patients selected from a prospective multicentre management study (SCORE). The Proseek Multiplex CVD III kit was used to simultaneously measure 92 plasma proteins in DVT and non-DVT patients. In total, plasma levels of 30 proteins were significantly different in DVT and non-DVT patients. However, after multiple testing correction by Bonferroni and Hochberg methods, levels of 7 proteins (SELP, TR, VWF, TFPI, OPN, BLM hydrolase and ST2) remained statistically different between DVT and non-DVT patients. SELP, VWF and TFPI are well known DVT-associated proteins, however; to best of our knowledge, the role of TR, OPN, BLM hydrolase and ST2 is not known in DVT patients and, for the first time, we show that they may have a role in DVT.
ROC analysis of these proteins yielded AUCs ranging from 0Á71 to 0Á84. Furthermore, analysis of various combinations of these biomarkers demonstrated that the combination of OPN and APC-PCI had the best diagnostic potential, with an AUC of 0Á94 compared to their individual analysis (OPN; AUC = 0Á72 and APC-PCI = 0Á88).
The most widely used diagnostic test for DVT is D-dimer, which can rule out DVT with high sensitivity; however, it has a limited value for ruling DVT in (lower specificity). Therefore, there is a need to identify diagnostic biomarkers which, individually or in combination with other biomarkers, can improve the diagnostic methods for DVT. To the best of our knowledge, this is the first study in which 92 CVD-specific proteins have been studied to identify potential biomarker/s for DVT.
Among the identified biomarkers, OPN combined with APC-PCI showed the best diagnostic potential for DVT detection with an AUC of 0Á94 and sensitivity of 89% and SELP  0Á84  0Á76-0Á92  0Á000001  8Á11  84%  71%  TR  0Á78  0Á69-0Á88  0Á000001  3Á66  82%  76%  VWF  0Á77  0Á67-0Á87  0Á00001  5Á42  64%  82%  TFPI  0Á74  0Á64-0Á85  0Á00001  7Á90  78%  64%  OPN  0Á72  0Á61-0Á82  0Á0004  4Á54  62%  73%  BLM hydrolase  0Á72  0Á62-0Á83  0Á0003  4Á28  67%  71%  ST2  0Á71  0Á60-0Á83  0Á0007  3Á34  62%  76%  APC-PCI  0Á88  0Á80- 
*Cut-off point obtained using the Youden index = max (specificity + sensitivity). For Vidas â D-dimer clinical cut-off according to manufacturer was used. -0Á984  0Á89%  0Á84%  APC-PCI, TR  0Á933  0Á887-0Á980  0Á87%  0Á84%  APC-PCI, SELP  0Á907  0Á846-0Á968  0Á80%  0Á89%  APC-PCI, VWF  0Á918  0Á861-0Á974  0Á84%  0Á84%  APC-PCI, TFPI  0Á879  0Á801-0Á958  0Á80%  0Á89%  APC-PCI, BLM hydrolase  0Á913  0Á856-0Á970  0Á78%  0Á96%  APC-PCI, OPN, TR  0Á943  0Á901-0Á985  0Á84%  0Á91% 95% CI, 95% confidence interval; APC-PCI, activated protein C-protein C inhibitor complex; AUC, area under the curve; BLM hydrolase, Bleomycin hydrolase; OPN, Osteopontin; SELP, P-selectin; ST2, ST2 protein; TFPI, Tissue factor pathway inhibitor; TR, Transferrin receptor protein 1; VWF, von Willebrand factor. specificity of 84% with the selected cut-off points. The diagnostic performance of APC-PCI combined with OPN, especially in terms of specificity, was better compared to D-dimer analysed in the same population previously (Elf et al, 2010) . Plasma concentrations of APC and its inhibitor, PCI, increase in hypercoagulable states and activation of coagulation system as measured by the APC-PCI concentration is not influenced by the inflammatory activity to the same extent as D-dimer. However, APC-PCI, in terms of sensitivity (74%) was inferior in diagnostic potential to D-dimer in the same population (Elf et al, 2010) . However, it should be noted that the D-dimer test has not been standardized between laboratories, assays and populations and additional studies in other settings are therefore needed. We show that, together with OPN, APC-PCI has a comparable sensitivity to D-dimer test and a much improved specificity of 84% compared to D-dimer and APC-PCI in the same population (Elf et al, 2010) . OPN was originally found in bones where it regulates the formation and calcification of bone tissue (Wexler et al, 1996) . However, since then OPN has been shown to be a multifunctional protein and is associated with multiple diseases (Patarca et al, 1993; Oates et al, 1997; Liaw et al, 1998; Yamate et al, 1998; Kiefer et al, 2010) including CVD (Gordin et al, 2014) . In CVD it is mainly linked to arterial diseases, such as angina, and no study as yet has shown its role in venous DVT. OPN is cleaved by thrombin at sites of tissue injury and this cleavage is critical for OPN function (Senger et al, 1994) . Furthermore, OPN has also been detected in urine samples of DVT patients (von Zur Muhlen et al, 2016) . Therefore, evidence is also accumulating for its involvement in DVT. This study is the first to show that levels of OPN are significantly associated with the markers of hypercoagulability, suggesting its role in coagulation, and propose OPN as a novel biomarker of DVT with a diagnostic potential, especially in combination with APC-PCI.
Other promising novel DVT biomarkers with diagnostic potential identified in this study were ST2, BLM hydrolase and TR. ST2 also known as interleukin-1 receptor-like-1 (IL1RL1), is a member of the Toll-like receptor superfamily. ST2 consists of transmembrane (ST2L) and soluble isoforms (sST2) and are expressed in endothelial cells and cardiac myocytes. Higher levels of sST2 have been shown to be associated with myocardial infarction (MI) and could predict future congestive heart failure or death due to MI. Even though the role of sST2 is well recognized as a biomarker of poor prognosis in patients with MI, its role in DVT is still unknown. ST2L is activated by interleukin 33 (IL33) and has both pro-and anti-inflammatory roles, whereas sST2, which we have investigated in this study, prevents signalling through ST2L by binding free IL33. A link between inflammation and coagulation has been recently established by demonstrating that IL33 induces tissue factor (TF, also termed factor III), the primary trigger of coagulation, in human endothelial cells. Our results, showing significantly higher levels of sST2 in DVT and its association with markers of hypercoagulability, suggest that it may also have a role in DVT (Stojkovic et al, 2016) .
Soluble TR (sTR) in plasma is a truncated form of the tissue receptor (TR), which mediates iron delivery to erythroblasts and an increase in sTR is an indication of iron depletion (Punnonen et al, 1998) . Furthermore, a relationship between iron haemostasis and thrombosis has been hypothesized (Roest et al, 1999; Sullivan, 1999) and a genetic correlation between sTR and the risk of thrombosis has also been suggested (Remacha et al, 2006) . However, to our knowledge this is the first study in which a relationship between sTR level and risk of thrombosis and its association with markers of hypercoagulability has been demonstrated.
BLM hydrolase is an aminohydrolase that is involved in homocysteine (Hcy) metabolism and defects in Hcy metabolism can lead to hyperhomocysteinaemia. Pathological manifestations of hyperhomocysteinaemia include vascular complications, which remain the major cause of morbidity and mortality in untreated patients. Even mild hyperhomocysteinaemia, which is quite prevalent in the general population, is associated with an increased risk of vascular events (Zimny et al, 2006) . Furthermore, studies of genetic and nutritional hyperhomocysteinaemia in animal models provide additional support for a causal role of Hcy in atherothrombosis (Borowczyk et al, 2012) . However, the role of BLM hydrolase in venous thrombosis is unknown. Our results show that BLM hydrolase is significantly associated with markers of coagulation as well as with a higher risk of DVT. Taken together, these results suggest that BLM hydrolase may also have a role in DVT pathogenesis and we propose it as a potential diagnostic biomarker for DVT.
We also identified previously well-established biomarkers, such as SELP, VWF and TFPI, in our study and confirmed their role in the risk of DVT. SELP has been a well-studied biomarker of DVT and has been shown to be a reliable diagnostic biomarker for DVT (Ay et al, 2007; Ramacciotti et al, 2011) , which is in agreement with our results. We also confirmed that SELP alone was the best diagnostic biomarker among all identified proteins. However, it was inferior in terms of AUC and sensitivity when compared with combination of OPN and APC-PCI. Combination of SELP and OPN did not improve their diagnostic potential when compared with OPN + APC-PCI. TFPI is an important regulator of TF-induced coagulation. TFPI inhibits the TF-activated factor VII (FVIIa) complex in an activated factor X (FXa)-dependent manner, thereby controlling thrombin generation and fibrin formation (Ellery & Adams, 2014) . We confirmed a previous report showing that TFPI is elevated in acute DVT (Sidelmann et al, 2008) . VWF is an acute phase reactant that is also known to be increased in patients with acute DVT (Sidelmann et al, 2008) . It is well established that VWF an important player in both haemostasis and thrombosis. It mediates adherence of platelets to injured vessel walls by binding both to the collagen and platelet receptor. VWF is also a Diagnostic biomarkers for DVT ª 2018 John Wiley & Sons Ltd carrier and protector of factor VIII, a main cofactor of the clotting pathway (Shahidi, 2017) .
One possible limitation of the study is that we have investigated 92 proteins in a matched case-control study; our results should therefore be interpreted with caution. However, we adjusted our results for multiple comparisons. In addition, because of the case-control nature of the study, the temporal relationship between the cause and effect cannot be determined. Nevertheless, this is an exploratory study in which 92 CVD-associated proteins have been evaluated in an effort to identify novel DVT biomarkers. The main strength of the study is that we have identified novel biomarkers which are associated with markers of hypercoagulability and we also confirm previous known associations with acute thrombosis: TFPI, VWF and SELP, indicating robustness of our results (Ay et al, 2007; Sidelmann et al, 2008; Ramacciotti et al, 2011) .
In conclusion, we have identified multiple novel biomarkers associated with the risk of DVT and present a profile of protein biomarkers that could contribute to the development of a powerful multi-marker test for the diagnosis of DVT.
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